Cart
sales@molnova.com
Cotosudil
CAS No. 1258833-31-6
Cotosudil( —— )
Catalog No. M35056 CAS No. 1258833-31-6
Cotosudil is a ROCK kinase inhibitor with antihypertensive activity and is used to treat or prevent diseases or conditions caused by cataracts, cardiovascular or neurodegenerative diseases or nerve damage.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 274 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 376 | In Stock |
|
| 25MG | 645 | In Stock |
|
| 50MG | 892 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCotosudil
-
NoteResearch use only, not for human use.
-
Brief DescriptionCotosudil is a ROCK kinase inhibitor with antihypertensive activity and is used to treat or prevent diseases or conditions caused by cataracts, cardiovascular or neurodegenerative diseases or nerve damage.
-
DescriptionCotosudil is a ROCK kinase inhibitor, which can be used for glaucoma or ocular hypertension research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetROCK
-
RecptorROCK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1258833-31-6
-
Formula Weight319.42
-
Molecular FormulaC16H21N3O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (156.53 mM; Ultrasonic (<60°C)
-
SMILESC[C@@H]1CNCCCCN1S(=O)(=O)c1ccc2cnccc2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. IYoshihiro Inoue, et al. Prophylactic or therapeutic agent for glaucoma or ocular hypertension. JP2013035802A.
molnova catalog
related products
-
SB-747651A Dihydroch...
SB-747651A dihydrochloride is a chemical compound that serves as an ATP-competitive inhibitor for mitogen- and stress-activated kinase 1 (MSK1), featuring an IC50 of 11 nM.
-
CID-5056270
CID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma, breast cancer and bone cancer.
-
RKI-1313
RKI-1313 was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion.
